Diffuse large B-cell lymphoma
Diffuse large B-cell lymphoma
Definition
Diffuse large B-cell lymphoma is the most common subtype of non-Hodgkin lymphoma (NHL) in adults characterized by a median age of presentation in the sixth decade of life (but also rarely occurring in adolescents and children) with the initial presentation being single or multiple rapidly growing masses (that may or may not be painful) in nodal or extranodal sites (such as thyroid, skin, breast, gastrointestinal tract, testes, bone, or brain) and that can be accompanied by symptoms of fever, night sweats and weight loss. DLBCL has an aggressive disease course, with the elderly having a poorer prognosis than younger patients, and with relapses being common.
Also known as diffuse large B-cell lymphoma, DLBCL — per MONDO
Also identified as
- DOID 0050745 per MONDO
- ICD10CM C83.3 per MONDO
- ICD9 200.7 per MONDO
- MESH D016403 per MONDO
- NCIT C8851 per MONDO
- Orphanet 544 per MONDO
- UMLS C0079744 per MONDO
Affected Organs
| Organ | Involvement | Source |
|---|---|---|
| Lymphoid system | Disease Has Primary Anatomic Site | NCIT · CC BY 4.0 |
Drugs indicated
| Drug | Relation | Source |
|---|---|---|
| Epcoritamab | may treat | MEDRT · Public domain (U.S. Government work) |
| Glofitamab | may treat | MEDRT · Public domain (U.S. Government work) |
| Loncastuximab Tesirine | may treat | MEDRT · Public domain (U.S. Government work) |
| Polatuzumab Vedotin | may treat | MEDRT · Public domain (U.S. Government work) |
| Tafasitamab | may treat | MEDRT · Public domain (U.S. Government work) |